Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of marketing authorisation for Orion's new intensive care sedative dexdor (dexmedetomidine).
Subscribe to our email newsletter
The company expects to get the European Commission’s marketing authorization approval for the intensive care sedative dexdor in few months.
When approved, the drug can be marketed by Orion in all the European Union Member States.
Dexmedetomidine is available with the brand name Precedex in more than 30 countries outside Europe, including the US (since 2000)and Japan.